ARA-290

Erythropoietin (EPO) is known primarily for stimulating red blood cell production. However, researchers discovered that EPO also has potent tissue-protective effects — preventing cell death, reducing inflammation, and promoting repair in multiple tissues including the brain, heart, and nerves. The problem is that these benefits come packaged with dangerous erythropoietic side effects (blood thickening, thrombosis).

ARA-290 was designed to capture EPO's tissue-protective effects without its blood-stimulating activity. It corresponds to a region on the surface of EPO's helix B that interacts with the innate repair receptor (IRR) — a distinct receptor from the classical EPO receptor responsible for erythropoiesis.

ARA-290 activates the innate repair receptor (IRR), triggering:

• Anti-apoptotic signaling: Activates JAK2/STAT3 and PI3K/Akt pathways in stressed cells, preventing programmed cell death
• Anti-inflammatory effects: Modulates macrophage and monocyte activation, reducing pro-inflammatory cytokine release
• Nerve repair: Promotes small fiber nerve regeneration — particularly relevant for neuropathy
• Tissue repair: Enhances endogenous repair mechanisms without promoting cell proliferation

Clinical trial dosing: 2–4 mg subcutaneous injection daily or three times weekly. Phase 2 trials in sarcoidosis neuropathy used 2 mg SC three times weekly for 28 days. ARA-290 has a half-life of approximately 2 minutes in plasma, but tissue-level effects persist much longer through downstream signaling cascades.

• Well-tolerated in clinical trials: No serious drug-related adverse events reported in Phase 1/2 studies
• No erythropoietic effects: Does not increase red blood cell production, hematocrit, or thrombosis risk
• Injection site reactions: Mild and transient
• Headache: Occasionally reported